ZINBRYTA (daclizumab), immunosuppressant
NEUROLOGY - New medicinal product
Opinions on drugs -
Posted on
Mar 13 2017
Reason for request
Inclusion
- ZINBRYTA, administered subcutaneously, has Marketing Authorisation in relapsing forms of multiple sclerosis (MS) in adults. This indication includes relapsing/remitting (RR) MS, relapsing secondary progressive (SP) MS and patients who presented a single demyelinising event.
- It is a therapeutic alternative usable in first or second-line treatment in all relapsing forms of MS.
- Its superiority has been demonstrated relative to a first-line treatment (interferon β1a AVONEX) in terms of annualised relapse rates to the detriment of a less-favourable safety profile, particularly with serious adverse events.
- The absence of direct comparison with treatments indicated in highly active forms of RRMS does not allow its contribution in these patients to be quantified.
- However, there are no data documenting its efficacy or safety in patients with relapsing SPMS.
Clinical Benefit
Substantial |
- |
Clinical Added Value
no clinical added value |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments